1. Assessing trends and variability in outpatient dual testing for chronic kidney disease with urine albumin and serum creatinine, 2009-2018: a retrospective cohort study in the Veterans Health Administration System.
- Author
-
Bhave, Nicole, Han, Yun, Steffick, Diane, Bragg-Gresham, Jennifer, Zivin, Kara, Burrows, Nilka, Pavkov, Meda, Tuot, Delphine, Saran, Rajiv, and Powe, Neil
- Subjects
GENERAL MEDICINE (see Internal Medicine) ,Nephrology ,Primary Health Care ,Humans ,United States ,Creatinine ,Veterans Health ,Retrospective Studies ,Outpatients ,Diabetes Mellitus ,Renal Insufficiency ,Chronic ,Veterans ,United States Department of Veterans Affairs - Abstract
BACKGROUND: Simultaneous urine testing for albumin (UAlb) and serum creatinine (SCr), that is, dual testing, is an accepted quality measure in the management of diabetes. As chronic kidney disease (CKD) is defined by both UAlb and SCr testing, this approach could be more widely adopted in kidney care. OBJECTIVE: We assessed time trends and facility-level variation in the performance of outpatient dual testing in the integrated Veterans Health Administration (VHA) system. DESIGN, SUBJECTS AND MAIN MEASURES: This retrospective cohort study included patients with any inpatient or outpatient visit to the VHA system during the period 2009-2018. Dual testing was defined as UAlb and SCr testing in the outpatient setting within a calendar year. We assessed time trends in dual testing by demographics, comorbidities, high-risk (eg, diabetes) specialty care and facilities. A generalised linear mixed-effects model was applied to explore individual and facility-level predictors of receiving dual testing. KEY RESULTS: We analysed data from approximately 6.9 million veterans per year. Dual testing increased, on average, from 17.4% to 21.2%, but varied substantially among VHA centres (0.3%-43.7% in 2018). Dual testing was strongly associated with diabetes (OR 10.4, 95% CI 10.3 to 10.5, p
- Published
- 2024